Abstract

Novel drug leads for malaria therapy are urgently needed because of the widespread emergence of resistance to all available drugs. Screening of the Harbor Branch enriched fraction library against the Plasmodium falciparum chloroquine-resistant strain (Dd2) followed by bioassay-guided fractionation led to the identification of two potent antiplasmodials; a novel diterpene designated as bebrycin A (1) and the known C21 degraded terpene nitenin (2). A SYBR Green I assay was used to establish a Dd2 EC50 of 1.08 ± 0.21 and 0.29 ± 0.02 µM for bebrycin A and nitenin, respectively. Further analysis was then performed to assess the stage specificity of the inhibitors antiplasmodial effects on the Dd2 intraerythrocytic life cycle. Exposure to bebrycin A was found to block parasite maturation at the schizont stage if added any time prior to late schizogony at 42 hours post invasion, (HPI). In contrast, early life cycle exposure to nitenin (prior to 18 HPI) was identified as crucial to parasite inhibition, suggesting nitenin may target the maturation of the parasite during the transition from ring to early trophozoite (6–18 HPI), a novel property among known antimalarials.

Highlights

  • Worldwide, malaria continues to be a prevalent infectious disease with an estimated209 million clinical cases in 2019, with children and pregnant women being most at risk [1,2].There remain limited treatment options due to the widespread prevalence of drug resistance among the disease causing Plasmodium spp. parasite

  • Previous studies of octocorals belonging to the genus Bebryce have led to the isolation of a number of different classes of organic compounds including carotenoids [18], a sterol glycoside [19], and a guaiazulene [20]

  • Bebrycin A is a diterpene with a rare C-15 membered carbocyclic ring

Read more

Summary

Introduction

Malaria continues to be a prevalent infectious disease with an estimated209 million clinical cases in 2019, with children and pregnant women being most at risk [1,2].There remain limited treatment options due to the widespread prevalence of drug resistance among the disease causing Plasmodium spp. parasite. Parasites are exhibiting signs of resistance against artemisinin partner drugs [6,7]. This grim situation underscores the urgent need to develop novel antimalarials acting on targets different from existing therapeutics. Marine organisms have long been a source of novel natural products with unique chemical scaffolds possessing a variety of potent biological activities [8]. This rich marine biodiversity provides us an enormous opportunity to identify novel antimalarial leads from specialized metabolites of marine organisms [9]

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call